2. Search Result
Search Result
Results for "

Axl+inhibitor

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12432
    Gilteritinib
    40+ Cited Publications

    ASP2215

    		 FLT3 TAM Receptor Cancer
    Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib
  • HY-15150
    Bemcentinib
    Maximum Cited Publications
    62 Publications Verification

    R428; BGB324

    		 TAM Receptor Cancer
    Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
    Bemcentinib
  • HY-12432A
    Gilteritinib hemifumarate
    40+ Cited Publications

    ASP2215 hemifumarate

    		 FLT3 TAM Receptor Cancer
    Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.
    Gilteritinib hemifumarate
  • HY-12432R
    Gilteritinib (Standard)

    ASP2215 (Standard)

    		 Reference Standards FLT3 TAM Receptor Cancer
    Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib (Standard)
  • HY-151904
    AXL-IN-13

    		TAM Receptor FLT3 PDGFR Cancer
    AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion .
    AXL-IN-13
  • HY-179105
    Axl-IN-20

    		TAM Receptor Cancer
    Axl-IN-20 (Compound w11) is a selective, orally active AXL inhibitor, with an IC50 of 5 nM. Axl-IN-20 has antitumor activity against hematological malignancies .
    Axl-IN-20
  • HY-12432S1
    Gilteritinib-d8

    ASP2215-d8

    		 FLT3 TAM Receptor Cancer
    Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
    Gilteritinib-d8
  • HY-146596
    Axl-IN-5

    		TAM Receptor Cancer
    Axl-IN-5 (compound 1) is a AXL inhibitor with an IC50 of 283 nM. Axl-IN-5 has anticancer effects .
    Axl-IN-5
  • HY-164382
    ER-851

    		TAM Receptor Cancer
    ER-851 is a selective AXL inhibitor with oral activity with IC50 of 100 nM. ER-851 has antitumor activity .
    ER-851
  • HY-15150R
    Bemcentinib (Standard)

    R428 (Standard); BGB324 (Standard)

    		 TAM Receptor Reference Standards Cancer
    Bemcentinib (Standard) is the analytical standard of Bemcentinib. This product is intended for research and analytical applications. Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
    Bemcentinib (Standard)
  • HY-15150G
    Bemcentinib (GMP)

    R428 (GMP); BGB324 (GMP)

    		 TAM Receptor Cancer
    Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
    Bemcentinib (GMP)
  • HY-153441
    AXL-IN-15

    		TAM Receptor Cancer
    AXL-IN-15 (cpd391) is a potent Axl inhibitor with both Ki and IC50 <1 nM. AXL-IN-15 can be used for research in cancer .
    AXL-IN-15
  • HY-162085
    Axl-IN-17

    		TAM Receptor Cancer
    Axl-IN-17 (compound 13c) is an orally active, selective AXL inhibitor with an IC50 value of 3.2 nM. Axl-IN-17 reveals antitumor efficacy .
    Axl-IN-17
  • HY-146615
    Axl-IN-6

    		TAM Receptor Cancer
    Axl-IN-6 (compound 14) is an orally active and potent AXL inhibitor. Axl-IN-6 is well tolerated and significantly inhibits the tumor growth in MV-4-11 subcutaneous xenograft model .
    Axl-IN-6
  • HY-150041
    TL4830031

    		TAM Receptor Cancer
    TL4830031 (compound 8i), a quinolone antibiotic derivatives, is a potent Axl inhibitor with an IC50 value of 26 nM. TL4830031 inhibits the phosphorylation of Axl. TL4830031 inhibits cell invasion and migration. TL4830031 can be used for cancer research .
    TL4830031
  • HY-147579
    Axl-IN-12

    		TAM Receptor Infection Inflammation/Immunology Cancer
    Axl-IN-12 (Example 2) is a potent AXL inhibitor. Axl-IN-12 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .
    Axl-IN-12
  • HY-147578
    Axl-IN-11

    		TAM Receptor Infection Inflammation/Immunology Cancer
    Axl-IN-11 (Example 1) is a potent AXL inhibitor. Axl-IN-11 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancers, viral infectious diseases or other diseases of mammals .
    Axl-IN-11
  • HY-W400801
    Denfivontinib hydrochloride

    G-749 hydrochloride

    		 TAM Receptor Cancer
    Denfivontinib (G-749) hydrochloride is an AXL inhibitor that has synergistic antitumor effects with the PD-1 inhibitor Pembrolizumab (HY-P9902). Denfivontinib can enhance the NOD-like receptor pathway, thereby promoting the formation of the NLRP3 inflammasome .
    Denfivontinib hydrochloride
  • HY-12432AR
    Gilteritinib hemifumarate (Standard)

    ASP2215 hemifumarate (Standard)

    		 FLT3 TAM Receptor Reference Standards Cancer
    Gilteritinib hemifumarate (Standard) is the analytical standard of Gilteritinib hemifumarate. This product is intended for research and analytical applications. Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively.
    Gilteritinib hemifumarate (Standard)
  • HY-147574
    Axl-IN-7

    		TAM Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease .
    Axl-IN-7
  • HY-149491
    HIV-IN-7

    		TAM Receptor HIF/HIF Prolyl-Hydroxylase Others
    Axl-IN-16 (Compound 4) is a Axl inhibitor. Axl-IN-16 inhibits Axl expression and inhibits the activity of HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 can be isolated from“fruiting liquid (FL)” of Hypholoma lateritium and Hericium erinaceus .
    HIV-IN-7
  • HY-152075
    AXL-IN-14

    		TAM Receptor Cancer
    AXL-IN-14 is a potent and orally active AXL inhibitor with an IC50 value of 0.8 nM. AXL-IN-14 inhibits Gas6/AXL-mediated cell migration and invasion. AXL-IN-14 decreases the expression of p-AXL and p-AKT proteins. AXL-IN-14 shows anti-tumor activity .
    AXL-IN-14
  • HY-147577
    Axl-IN-10

    		TAM Receptor Inflammation/Immunology Cancer
    Axl-IN-10 (Example 1) is a potent AXL inhibitor, with an IC50 of 5 nM. Axl-IN-10 has excellent transmembrane properties.Axl-IN-10 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-10 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .
    Axl-IN-10
  • HY-170954
    C-Met/Axl-IN-1

    		Apoptosis c-Met/HGFR TAM Receptor Cancer
    C-Met/Axl-IN-1 (Compound 22a) is an orally active and selective type II c-Met/Axl inhibitor with IC50 values of 1 nM and 10 nM, respectively. C-Met/Axl-IN-1 can inhibit proliferation, induce cell cycle arrest and apoptosis of tumor cells. C-Met/Axl-IN-1 has strong anti-tumor activity .
    C-Met/Axl-IN-1
  • HY-147576
    Axl-IN-9

    		TAM Receptor Inflammation/Immunology Cancer
    Axl-IN-9 (Example 10) is a potent AXL inhibitor, with an IC50 of 26 nM. Axl-IN-9 has excellent transmembrane properties. Axl-IN-9 exhibits excellent pharmacokinetic properties in an animal body. Axl-IN-9 can be used for the research of proliferative diseases, autoimmune diseases, allergic diseases, inflammatory diseases, transplant rejection, cancer, or other diseases in mammals .
    Axl-IN-9
  • HY-162940
    MerTK/Axl-IN-1

    		TAM Receptor Inflammation/Immunology Cancer
    MerTK/Axl-IN-1 (Compound A-910) is a potent and selective dual MerTK/Axl inhibitor, with IC50s of 4.2 and 8.8 nM in Ba/F3, and 0.2 and 0.9 nM in HTRF. MerTK/Axl-IN-1 results in pMerTK inhibition in vivo. MerTK/Axl-IN-1 has long half-life, high oral exposure and bioavailability .
    MerTK/Axl-IN-1
  • HY-147575
    Axl-IN-8

    		TAM Receptor c-Met/HGFR Cancer
    Axl-IN-8 (NO.1) is a potent AXL inhibitor, with an IC50 of <1 nM. Axl-IN-8 also inhibits c-MET, with an IC50 of 1-10 nM. Axl-IN-8 shows anti-proliferative activity against BaF3/TEL-AXL, MKN45, and EBC-1 cells, with IC50 values of <10, 226.6 and 120.3 nM, respectively .
    Axl-IN-8
  • HY-162103
    Axl-IN-18

    		TAM Receptor Apoptosis Cancer
    Axl-IN-18 (compound 25c) is a potent and selective type II AXL inhibitor. Axl-IN-18 shows excellent AXL inhibitory activity (IC50=1.1 nM) and 343-fold selectivity over the highly homologous kinase MET in biochemical assays (IC50=377 nM). Axl-IN-18 significantly inhibits AXL-driven cell proliferation, dose-dependently suppresses 4T1 cell migration and invasion, and induces apoptosis. Axl-IN-18 shows noticeable antitumor efficacy in a BaF3/TEL-AXL xenograft model .
    Axl-IN-18
  • HY-15150C
    (R)-Bemcentinib

    (R)-R428; (R)-BGB324

    		 Drug Isomer Cancer
    (R)-Bemcentinib ((R)-R428) is the R-isomer of Bemcentinib (HY-15150). Bemcentinib (R428) is a selective, orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib blocks tumor metastasis and prolongs survival in metastatic breast cancer models .
    (R)-Bemcentinib
  • HY-15150S
    Bemcentinib-d8

    R428-d8; BGB324-d8

    		 Isotope-Labeled Compounds TAM Receptor Cancer
    Bemcentinib-d8 (R428-d8) is the deuterium labeled Bemcentinib (HY-15150). Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
    Bemcentinib-d8
  • HY-179535
    Axl-IN-21

    		TAM Receptor Discoidin Domain Receptor TGF-β Receptor Hedgehog Cancer
    Axl-IN-21 is an orally active and selective AXL inhibitor (Kd = 2.7 nM, IC50 = 4.0 nM). Axl-IN-21 displays kinase selectivity and retains strong activity against cancer-related mul-kinases (Mer with Kd = 1.4 nM, DDR1 with IC50 = 22.2 nM, HIPK4 with Kd = 11.0 nM and LOK with Kd =10 nM). Axl-IN-21 overcomes tumor microenvironment-driven resistance by blocking CAF-derived GAS6-induced AXL/STAT3/ABCG1 signaling, restoring chemosensitivity and inhibiting drug efflux in gastric cancer (GC). Axl-IN-21 suppresses TGF-β1-induced epithelial-mesenchymal transition (EMT), migration, and invasion in MDA-MB-231 cells. Axl-IN-21 exhibits no significant cytotoxicity in non-cancerous cells. Axl-IN-21 can be research for triple negative breast cancer and gastric cancer [1] [2] .
    Axl-IN-21

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: